NCT Number: NCT00191295
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for future studies?
Notify MeKey information
Conditions
Age range
6 year–18 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2 / Phase 3
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Aichi, Japan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients are diagnosed with ADHD
- Patients must be able to swallow capsules
- Patients must be of normal intelligence
Exclusion criteria
- Patients who weigh less than 15 kg or more than 75 kg
- Patients with organic brain disease (for example, dementia or traumatic brain injury residual)
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Change of total score on ADHD RS-IV-JParent Version: Investigation-Administered and Scored
Secondary outcomes
-
Relationship between atomoxetine doses and both efficacy and safety variables
-
Plasma concentration of atomoxetine and its metabolites
-
Changes on ADHD RS-IV-J-School Version score
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Official study title
A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder
Important dates
- Study start
- 2005
- Study completion
- 2006
- First posted
- Sep 19, 2005
- Registry last updated
- Nov 6, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
NCT05631626
ADHD, ADHD - Combined Type
Las Vegas, Nevada, United States
View Trial DetailsA Systematic Study of Assessment of Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT05588713
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Uppsala, Sweden
View Trial DetailsVirtual Reality and Diagnostic of Attention Deficit Hyperactivity Disorder (ADHD) (PADA1)
NCT04561713
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Bordeaux, France
View Trial DetailsBUILT Family Lifestyle Program for Children With ADHD
NCT05464056
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Chicago, Illinois, United States
View Trial Details